Related Experiment Video

Updated: Nov 3, 2025

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

784

A novel miRNA biomarker panel associated with mortality in pediatric patients with ARDS

Lisa K Lee1, Mansoureh Eghbali2, Anil Sapru3

  • 1Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Suite 3325, Los Angeles, CA, 90095, USA. lklee@mednet.ucla.edu.

Respiratory Research
|June 5, 2021
PubMed

Insights

A new panel of 6 microRNAs can predict mortality in pediatric acute respiratory distress syndrome (ARDS). These microRNAs may offer new therapeutic targets for ARDS treatment.

Area of Science:

  • Biomarkers
  • Molecular Biology
  • Pediatric Critical Care Medicine

Background:

  • Pediatric acute respiratory distress syndrome (ARDS) presents a significant challenge in critical care.
  • Identifying reliable biomarkers for mortality prediction in pediatric ARDS is crucial for timely intervention.

Discussion:

  • A novel panel of six microRNAs has been identified as a predictor of mortality in pediatric ARDS.
  • These microRNAs show potential mechanistic roles in the pathophysiology of ARDS.
  • The findings suggest these microRNAs could be investigated as therapeutic targets.

Key Insights:

  • Discovery of a 6-microRNA signature for predicting mortality in pediatric ARDS.
  • Established potential mechanistic links between these microRNAs and ARDS.
  • Identified potential novel pharmacologic targets for ARDS treatment.

Outlook:

  • Further validation of the microRNA panel in larger cohorts is warranted.
  • Investigating the precise molecular mechanisms of these microRNAs in ARDS.
  • Exploring the therapeutic potential of targeting these microRNAs for improved pediatric ARDS outcomes.
Keywords:
ARDSBiomarkersPediatricsmiRNA

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.9K
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

12.1K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
284
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
592